SEC Form 4 · accession 0001179110-16-028587
Assertio Therapeutics, Inc · ASRT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
August J Moretti
Officer — Chief Financial Officer & SVP
Period of report
Aug 10, 2016
Accepted (ET)
Aug 11, 2016 · 5:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001005201
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF1,F3,F2 | Aug 10, 2016 | S | 1,703 | $21.40 | D | 21,680 | D | |
| Common Stock | Aug 10, 2016 | M | 3,297 | $12.69 | A | 24,977 | D | |
| Common StockF1,F3,F2 | Aug 10, 2016 | S | 3,297 | $21.40 | D | 21,680 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common StockF4 | $12.69 | Aug 10, 2016 | M | 3,297 | D | — | Feb 18, 2024 | Common Stock | 3,297 | 53,741 | D |
Explanation of responses
- F1Represents shares sold pursuant to a 10b5-1 plan adopted on March 12, 2015.
- F2Amount does not include any unvested restricted stock previously reported on Form 4 by the reporting person.
- F3The price reported is a weighted average price. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares at each price within the range set forth in this footnote.
- F457,038 stock options were granted on February 18, 2014 and were exercisable in 48 equal monthly installments.